Related Experiment Video
Updated: Oct 15, 2025
Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
Zimberelimab: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Abstract:
Zimberelimab (®) is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lung cancer and classical Hodgkin's lymphoma. Based on the results of a phase II trial, zimberelimab was recently approved for marketing in China as treatment for relapsed or refractory classical Hodgkin's lymphoma. This article summarizes the milestones in the development of zimberelimab leading to this first approval.
Insights
Zimberelimab, an anti-programmed cell death protein-1 (PD-1) antibody, has gained marketing approval in China for relapsed or refractory classical Hodgkin
Area of Science:
- Immunotherapy
- Oncology
- Pharmacology
Background:
- Zimberelimab is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody.
- It is being developed for various cancers, including cervical cancer, non-small cell lung cancer, and classical Hodgkin's lymphoma.
- Developed by Gloria Biosciences, Arcus Biosciences, and Taiho Pharmaceutical Co.
Purpose of the Study:
- To summarize the development milestones of zimberelimab.
- To highlight the drug's journey leading to its first marketing approval.
Main Methods:
- Review of development milestones.
- Analysis of phase II trial results.
Main Results:
- Zimberelimab demonstrated efficacy in a phase II trial.
- Based on these results, marketing approval was granted in China.
Conclusions:
- Zimberelimab is now approved in China for relapsed or refractory classical Hodgkin's lymphoma.
- This marks a significant milestone in the drug's development and availability.
More Related Videos
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022